Document is current
Any future updates will be listed below
-
Authors
Lu, Jingyi https://orcid.org/0000-0002-0510-5034
ter Voert, Michèle A. https://orcid.org/0009-0000-6606-8030
Ünal, Mehtap https://orcid.org/0000-0002-0308-0291
Whitfield, Natalie N.
Liesenfeld, Oliver
ter Maaten, Jan C. https://orcid.org/0000-0002-0353-4011
Sweeney, Timothy E.
Bouma, Hjalmar R. https://orcid.org/0000-0003-1032-321X
-
Funding
Funding for this research was provided by:
Health~Holland (PPP-2021-24)
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 12 February 2025
First Online: 21 February 2025
Declarations
:
: The study was approved by the local Medical Ethics Review Committee under protocol number 16775 and conducted according to the principles of the World Medical Association Declaration of Helsinki.
: Not applicable.
: NW is an employee and stock option holder for Inflammatix. OL is an advisor and a stock option holder for Inflammatix. TS is an employee and stock option holder for Inflammatix.
